ANAKINRA IN RECURRENT PERICARDITIS: CURRENT EVIDENCE ON CLINICAL USE, EFFECTIVENESS AND SAFETY
Interleukin-1 receptor antagonist
Recurrent pericarditis
Pericardite
Interleucina-1
Anakinra
Interleukin-1 receptor antagonist
Recurrent pericarditis
Abstract
Anakinra is a recombinant human interleukin 1 receptor antagonist that competes and blocks the biologic effects of interleukin 1, reducing systemic inflammatory responses. In the 2015 guidelines for the diagnosis and management of pericardial diseases of the European Society of Cardiology, anakinra was established as a third-line therapy option for refractory recurrent pericarditis (RP). Recently, important studies that investigates the effect and safety of anakinra in RP were published, such as the AIRTRIP trial and the International Registry of Anakinra for Pericarditis. This article presents the current evidence about the effectiveness and safety of anakinra in RP and discusses its clinical application and mechanisms.
[Texto sem Formatação]
[Texto sem Formatação]
Author
Document type
Artigo de periódicosPublisher
Taylor Walker
Source
CORREIA, Eduardo Thadeu de Oliveira. Anakinra in recurrent pericarditis: current evidence on clinical use, effectiveness, and safety. Journal of Cardiovascular Pharmacology, v. 76, n. 1, p. 42-49, Jul. 2020. Disponível em: https://journals.lww.com/cardiovascularpharm/Fulltext/2020/07000/Anakinra_in_Recurrent_Pericarditis__Current.5.aspxSubject(s)
AnakinraInterleukin-1 receptor antagonist
Recurrent pericarditis
Pericardite
Interleucina-1
Anakinra
Interleukin-1 receptor antagonist
Recurrent pericarditis